Form 4 for BMEA Biomea Fusion, Inc.
Accepted 2021-09-21 00:00:00 ET · period of report 2021-09-17 · accession 0000899243-21-036767 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2021-09-21 | 2021-09-17 | BMEA | Stergiopoulos Sotirios | Dir | P - Purchase | $10.96 | +34.7K | 4.40M | +0.8% | +$379.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-17 | P | A | 34,658 | $10.96 | 4,400,000 | I See footnote | — | — | (F1) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and an affiliate of A2A Pharmaceuticals Inc. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. |